This article is more than 5 years old. Information may no longer be current.

Merck's third quarter generates $12 billion in sales

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WHITEHOUSE STATION, N.J. — Merck global sales in the third quarter were up 8% from the third quarter 2010 to $12.02 billion, according to a company press release.

As a result, the company raised its financial targets for the year. Full-year revenue is now expected to rise in the mid-single digit percent range over the $46 billion total in 2010, the release said.

Merck's key ophthalmic products, Cosopt (dorzolamide hydrochloride, timolol maleate) and Trusopt (dorzolamide hydrochloride ophthalmic solution), combined for total sales of $124 million, according to the release, an increase of 9% over the third quarter 2010.

"Going forward, Merck will continue to implement our growth strategy, while transforming the way we operate our business," Kenneth C. Frazier, Merck's president and CEO, said in the release. "Three consecutive quarters of top and bottom line growth demonstrate our ability to consistently perform while at the same time make the strategic investments necessary for the future. We remain focused on driving innovation and value for our customers and shareholders over the long term."